Trump Signs USCIRF and ALS Research Reauthorization: HR 1744 and HR 8205 Explained
President Trump signed two bills into law on Tuesday, November 3, 2026. H.R. 1744 reauthorizes the US Commission on International Religious Freedom through fiscal year 2028. H.R. 8205, the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026, extends federal programs supporting the development of therapies for Amyotrophic Lateral Sclerosis — a fatal neurodegenerative disease — through fiscal year 2031. The signing of H.R. 1744 and H.R. 8205 into law reauthorizes two existing programs: one that tracks global religious persecution, one that supports federal efforts to accelerate ALS therapy development.
Religious freedom advocates gain continued operations of an independent federal body that tracks and reports on global persecution through fiscal year 2028. ALS patients and researchers gain extended federal support for programs directed at accelerating therapy development for a disease that has historically seen few treatment options reach approval. Neither bill creates a new agency or launches a new program. Both extend systems that already exist. That distinction matters for understanding what this legislative agenda is doing.
What Is USCIRF, and What Does H.R. 1744 Actually Do?
The United States Commission on International Religious Freedom is an independent, bipartisan federal body. Congress created it through the International Religious Freedom Act of 1998. Its job is to monitor religious freedom violations around the world and report its findings to Congress and the President. USCIRF recommends annual Country of Particular Concern designations — a formal list of nations where religious persecution is severe and systematic. China, Russia, Iran, North Korea, and Saudi Arabia have appeared on that list in recent years. These designations shape US foreign policy decisions, sanctions recommendations, and diplomatic priorities.
USCIRF does not set policy itself. It observes, documents, and recommends. Its value lies in its independence — it operates separately from the State Department, which means it can report on any country regardless of the diplomatic relationship the US holds with that government at any given moment. H.R. 1744 extends that independent capacity through fiscal year 2028. The commission will continue to operate, continue to issue its annual reports, and continue to make its country recommendations for at least two more years.
What is the US Commission on International Religious Freedom (USCIRF)?
USCIRF is an independent, bipartisan federal body that monitors and reports on religious freedom violations abroad. It recommends Countries of Particular Concern — including China, Russia, Iran, and Saudi Arabia — and recommends policy responses to Congress and the President. It operates separately from the State Department, allowing it to report on any country regardless of current US diplomatic ties. H.R. 1744, signed into law on November 3, 2026, reauthorizes USCIRF through fiscal year 2028, securing its operations and annual reporting through at least 2028.
Why USCIRF’s Extension Through 2028 Carries Weight
The reauthorization through fiscal year 2028 locks in a foreign-policy monitoring instrument that future administrations will inherit. Any administration that follows the current one will receive a fully operational, funded, and legally authorized religious freedom monitoring body. That continuity means USCIRF’s annual reports will document whatever happens in global religious freedom during the transition between this administration and the next — including the full period when any Russia-Ukraine peace settlement is being negotiated, implemented, and tested. An independent federal body producing public reports on religious freedom in both countries throughout that window is a governance instrument with real weight. For the broader context on the Russia-Ukraine diplomatic situation, see our coverage of Melania Trump’s historic Russia-Ukraine diplomacy at the White House.
What H.R. 8205 Does for ALS Research and Treatment Access
H.R. 8205, the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026, extends federal programs established under the original Accelerating Access to Critical Therapies for ALS Act. ALS — Amyotrophic Lateral Sclerosis, commonly known as Lou Gehrig’s disease — is a progressive neurodegenerative disease that destroys the nerve cells controlling movement. It is uniformly fatal. Most patients live two to five years after diagnosis, and no known cure exists.
The original act directed the Food and Drug Administration to advance ALS treatment development through a structured set of requirements: holding regular public meetings with ALS patients, caregivers, researchers, and advocates; developing and updating a strategic plan for expediting ALS therapy development; and reporting to Congress on the state of ALS drug development. These requirements were designed to bring the FDA into more systematic coordination with the ALS research community and reduce the time from laboratory findings to available treatments.
The 2026 reauthorization extends those requirements through fiscal year 2031. The FDA’s structured engagement with ALS stakeholders — the meetings, the strategic planning, the congressional reporting — continues under renewed authorization. For the ALS community, the reauthorization maintains a federal framework that did not exist before the original act was passed. The number of ALS therapies that have reached clinical use remains limited. The federal programs this bill extends represent a sustained institutional commitment to changing that.
The Shared Logic Behind Both Bills
One bill extends the US government’s capacity to monitor global religious persecution. The other extends federal support for accelerating ALS therapy development. Both reflect the same governing approach: strengthen and extend existing programs rather than build new ones. USCIRF already existed. The FDA’s ALS therapy programs already existed. H.R. 1744 and H.R. 8205 gave both a firmer legal footing and an extended operational mandate. For context on the administration’s broader record in this area, see our coverage of Trump administration foreign policy and human rights.
The USCIRF extension through 2028 also carries a structural observation that routine coverage has not addressed. This reauthorization window ensures that USCIRF’s annual reports will document the full period in which any Russia-Ukraine peace settlement is being negotiated and monitored — producing an independent public record of religious freedom conditions in both countries throughout that process. That is a governance instrument that arrives in the hands of any future administration already operating, already funded, and already issuing reports. No future administration needs to build it. No future administration can quietly let it lapse mid-settlement.
Implementation and What to Watch
USCIRF’s operational continuity is immediate. The commission was already operating, and the reauthorization ensures it continues without interruption through fiscal year 2028. Its next annual report — expected in 2027 — will be the first published under the new authorization window. That report will cover all countries under review, including those directly affected by ongoing conflict.
For H.R. 8205, implementation means the FDA continues its structured engagement with the ALS research community under the program’s established framework. The next required update to the FDA’s strategic plan for ALS therapy development will be the first milestone under the extended authorization. ALS patients, researchers, and advocacy organizations will be watching whether the renewed federal commitment accelerates the pace of therapy approvals for a disease that has historically seen few treatment options reach patients.
President Trump signed H.R. 1744 and H.R. 8205 on November 3, 2026. USCIRF is reauthorized through fiscal year 2028. The FDA’s ALS therapy development programs continue under extended authorization through fiscal year 2031. Both laws are in effect.